Successful Treatment with Rituximab for Granulomatosis with Polyangiitis and Multiple Cranial Neuropathies

Wegener’s granulomatosis and multiple cranial neuropathies

Wegener’s granulomatosis, first described by Friedrich Wegener in 1936, is a systemic vasculitis that characteristically causes necrotizing granulomas of the respiratory tract and necrotizing cresentic glomerulonephritis. This article describes the history and modern treatment of the disease in conjunction with a clinical case.

Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.

BACKGROUND The general consensus is that for patients with EGPA with poor prognosis, intensive therapy with both GC and CF is indicated. The maintenance of remission is made with GC and AZA. A considerable number of patients with EGPA are refractory to first line therapy, experience dose-limiting side effects or relapse. In clinical trials, RTX was effective for the treatment of ANCA-associated...

Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis

Granulomatosis with polyangiitis and microscopic polyangiitis are small vessel vasculitides characterized by circulating antineutrophil circulating antibodies. Standard treatment for active severe disease has consisted of cyclophosphamide with glucocorticoids with or without plasmapheresis, which achieves approximately 75% sustained remission, but carries significant adverse effects such as mal...

Perianal Crohn Disease after Treatment with Rituximab for Active Granulomatosis with Polyangiitis.

Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab

Wegener's Granulomatosis (WG) is a systemic vasculitis typically associated with antineutrophil cytoplasmic antibodies (ANCAs). A small proportion of patients are ANCA negative, however, and this is more commonly found in individuals with disease limited to the ears, nose, throat, and lungs, who do not have renal involvement. Rituximab is a monoclonal anti-CD20 antibody that has been demonstrat...